Jenny Valladeau-Guilemond
Overview
Explore the profile of Jenny Valladeau-Guilemond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gobbini E, Hubert M, Doffin A, Eberhardt A, Hermet L, Li D, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39774795
Dendritic cells (DCs) are promising targets for cancer immunotherapies because of their central role in the initiation and control of immune responses. The rare cDC1 population is of particular interest...
2.
Page A, Chuvin N, Valladeau-Guilemond J, Depil S
Cell Mol Immunol
. 2024 Mar;
21(4):315-331.
PMID: 38443448
Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field of cancer treatment. Early clinical trials have shown promising outcomes, alongside satisfactory product efficacy and safety. Recent developments...
3.
Rocca Y, Voissiere A, Valladeau-Guilemond J, Bendriss-Vermare N
Methods Mol Biol
. 2023 Mar;
2618:187-197.
PMID: 36905518
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that have the ability to orchestrate adaptive and innate immune responses by antigen phagocytosis and T cell activation across different inflammatory settings...
4.
Sakref C, Bendriss-Vermare N, Valladeau-Guilemond J
Methods Mol Biol
. 2023 Mar;
2618:17-35.
PMID: 36905506
Dendritic cells (DCs) play a key role in the antitumor immunity, as they are at the interface of innate and adaptive immunity. This important task can only be performed thanks...
5.
Bayerl F, Bejarano D, Bertacchi G, Doffin A, Gobbini E, Hubert M, et al.
Eur J Immunol
. 2023 Jan;
53(11):e2249923.
PMID: 36623939
This article is part of the Dendritic Cell Guidelines article series, which provides a collection of state-of-the-art protocols for the preparation, phenotype analysis by flow cytometry, generation, fluorescence microscopy, and...
6.
Sosa Cuevas E, Valladeau-Guilemond J, Mouret S, Roubinet B, De Fraipont F, Landemarre L, et al.
Front Immunol
. 2022 Nov;
13:1040600.
PMID: 36353633
Subversion of immunity by tumors is a crucial step for their development. Dendritic cells (DCs) are strategic immune cells that orchestrate anti-tumor immune responses but display altered functions in cancer....
7.
Hubert M, Caux C, Valladeau-Guilemond J
Cancer Immunol Res
. 2022 Jul;
10(8):918.
PMID: 35802596
In this issue of Cancer Immunology Research, Ferris and colleagues demonstrate that type 1 conventional DC (cDC1) vaccines drive tumor rejection through direct antigen presentation, without the need of endogenous...
8.
Sosa Cuevas E, Bendriss-Vermare N, Mouret S, De Fraipont F, Charles J, Valladeau-Guilemond J, et al.
Clin Transl Immunology
. 2022 May;
11(5):e1382.
PMID: 35517992
Objectives: Plasmacytoid DCs (pDCs) play a critical yet enigmatic role in antitumor immunity through their pleiotropic immunomodulatory functions. Despite proof of pDC diversity in several physiological or pathological contexts, pDCs...
9.
Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N, et al.
Sci Adv
. 2022 Jan;
8(4):eabj3671.
PMID: 35080970
Human endogenous retroviruses (HERVs) represent 8% of the human genome. HERV products may represent tumor antigens relevant for cancer immunotherapy. We developed a bioinformatic approach to identify shared CD8 T...
10.
Mattiuz R, Brousse C, Ambrosini M, Cancel J, Bessou G, Mussard J, et al.
Clin Transl Immunology
. 2021 Jul;
10(7):e1305.
PMID: 34277006
Objectives: To better understand how immune responses may be harnessed against breast cancer, we investigated which immune cell types and signalling pathways are required for spontaneous control of a mouse...